Copyright
©The Author(s) 2021.
World J Gastrointest Surg. Oct 27, 2021; 13(10): 1149-1165
Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1149
Published online Oct 27, 2021. doi: 10.4240/wjgs.v13.i10.1149
Ref. | Pts, n (%) | LOS (day) | Size (cm) | location from the AV (cm) | Pathology | R0 (%) | SF, n (%) | CR (%) | ||||||||||
AD | NET | AC | pCR | T0 | Tis | T1 | T2 | T3 | GIST | Other | ||||||||
Atallah et al[13], 2010 | 6 | 5/6 | 3 | 9 | 3 | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 83.3 | 0 | 100 | |
Van den Boezem et al[55], 2011 | 12 | 1 | 3.5 | 7 | 9 | 0 | 3 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 100 | 0 | 75.0 | |
Hompes et al[56], 2012 | 14 | 0.7 (0-5) | 3.4 | 5 | 6 | 1 | 6 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | Residual rectal fold (1) | 85.7 | - | 85.7 |
Lim et al[26], 2012 | 16 | 3 (2-6) | 0.5 (0-1.5) | 7.5 (4-10) | 0 | 4 | 11 | 5 | 0 | 1 | 3 | 1 | 1 | 0 | Mucocele (1) | 100 | - | 100 |
Barendse et al[57], 2012 | 15 | 2.5 | 3.6 | 6 | 7 | 1 | 4 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | Fibrosis (1) | 92.3 | - | - |
Alessandro et al[58], 2012 | 8 | 1 | - | 6.5 | 5 | 0 | 3 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 100 | 0 | - | |
Ragupathi et al[59], 2012 | 20 | 1.1 | 3.0 | 10.6 | 14 | 6 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 95.0 | - | 95 | |
Canda et al[60], 2012 | 6 | - | 4.75 | 7.2 | 5 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 100 | 0 | 83.3 | |
Albert et al[30], 2013 | 50 | 0.6 (0-6) | 2.75 | 8.2 | 23 | 2 | 23 | 0 | 0 | 1 | 16 | 3 | 3 | 0 | HP (2) | 94.0 | 2 | 98 |
Sevá-Pereira et al[61], 2014 | 5 | 1 | 4 (2-6) | 4 (1-6) | 2 | 0 | 4 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 100 | 0 | 60 | |
McLemore et al[27], 2014 | 32 | 2.5 (1-10) | 3 (0.5-7.5) | 4.1 (1-11) | 10 | 2 | 11 | 0 | 0 | 1 | 6 | 4 | 0 | 0 | NRT (9) | 100 | - | 90.6 |
Schiphorst et al[53], 2014 | 37 | 1 (1-23) | 4.2 | 7 | 23 | 0 | 12 | 0 | 0 | 6 | 4 | 1 | 1 | 0 | NRT (1) | 78.4 | 0 | 100 |
Lee and Lee[28], 2014 | 25 | 4 (3-8) | 2.3 (0.6-6) | 9 (6-17) | 6 | 9 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | NRT (6) | 100 | 0 | 80 |
Hahnloser et al[33], 2015 | 75 | 3.4 (1-21) | 4 | 6.4 | 35 | 1 | 38 | 3 | 4 | 11 | 13 | 9 | 1 | 0 | Hamartoma (1); NRT (4) | 96.0 | 6 | - |
Karakayali et al[51], 2015 | 10 | 0 | 2.6 (0.4-5) | 5.6 (3-10) | 1 | 0 | 9 | 0 | 0 | 5 | 4 | 0 | 0 | 0 | 100 | 0 | 50 | |
Gill et al[62], 2015 | 32 | 1.1 (0-4) | 2.1 (0.3-5) | 7.5 (2-13) | 11 | 4 | 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Hamartoma (1); HP (1); NRT (10) | 100 | 0 | 78.1 |
Noura et al[49], 2016 | 6 | 7 (6-8) | 2.4 (1.5-3.0) | 4.3 (3-6) | 0 | 0 | 6 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 100 | - | - | |
Quaresima et al[63], 2016 | 31 | 3 (2-7) | 2.4 (1-5) | 9.5 (6-15) | 10 | 2 | 17 | 0 | 0 | 0 | 17 | 0 | 0 | 2 | 96.8 | - | - | |
Keller et al[35], 2016 | 75 | 1 (0-6) | 3.2 | 10 (6-16) | 59 | 0 | 17 | 0 | 6 | 0 | 6 | 4 | 1 | 0 | 93.3 | 1 | 85.3 | |
Sumrien et al[43], 2016 | 28 | 1.5 (0-4) | 4.4 (1.2-11.5) | - | 17 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 75.0 | 5 | - | |
Verseveld et al[52], 2016 | 24 | 1 (1-3) | 2.4 | 8 (2-17) | 20 | 0 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | - | - | - | |
Melin et al[64], 2016 | 29 | - | 3.9 | 6.79 | 23 | 0 | 6 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 89.7 | - | - | |
Mege et al[65], 2017 | 33 | 4 (1-60) | 4 (1-10) | 9 (0-12) | 24 | 0 | 9 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | NRT (1) | 78.8 | - | - |
Lee et al[24], 2018 | 200 | 1 | 2.9 | 7.2 (2-17) | 85 | 10 | 100 | 3 | 11 | 25 | 41 | 10 | 10 | 0 | NRT (11) | 93.0 | 9 | 94.5 |
García-Flórez et al[66], 2017 | 32 | - | 3.4 | 5.6 (4-10) | 15 | 1 | 12 | 0 | 0 | 0 | 4 | 4 | 4 | 1 | Pelvic abscess (1) | 96.9 | 2 | 84.4 |
Caycedo-Marulanda et al[44], 2017 | 50 | 1.1 | 2.5 (1-4.9) | 7 (2-15) | 23 | 1 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Lipoma (1) | 84.0 | 4 | 72.0 |
Clermonts et al[67], 2017 | 42 | 1 (1-24) | 4.3 | 7.5 (0-19) | 26 | 0 | 16 | 0 | 0 | 5 | 10 | 1 | 0 | 0 | 90.5 | 0 | - | |
Lee et al[42], 2017 | 181 | 0 | 2.8 | 6.1 | 75 | 8 | 96 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 92.8 | 9 | 73.5 |
Lee et al[68], 2017 | 35 | 4 (3-7) | - | 5 (4-9) | 0 | 0 | 35 | 18 | 0 | 2 | 4 | 9 | 2 | 0 | 97.1 | - | - | |
Chen et al[69], 2018 | 25 | 2.7 | 1.1 | 8.4 | 3 | 16 | 6 | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 80.0 | - | - | |
Clermonts et al[48], 2018 | 37 | 1 (1-5) | 4.8 | 6.5 (0-19) | 23 | 0 | 14 | 0 | 0 | 5 | 8 | 1 | 0 | 0 | 89.2 | 0 | - | |
Dufresne et al[70], 2018 | 5 | - | - | 11 (8-14) | 2 | 1 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 80.0 | - | - | |
Llano et al[71], 2019 | 27 | 1.1 | 5.3 (2-9) | 7 (5-9) | 14 | 5 | 6 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | Cicatrical fibrosis (1); Leiomyoma (1) | 1 | 2 | - |
Westrich et al[72], 2019 | 38 | 3 (1-7) | 4 (1.5-9.0) | 8 (5-12) | 19 | 2 | 11 | 0 | 0 | 1 | 8 | 1 | 1 | 0 | Granulation (8) | 4 | 4 | 89.5 |
Van den Eynde et al[73], 2019 | 68 | 2 (1-3) | 4.5 | 6 (5-10) | 44 | 0 | 24 | 0 | 6 | 0 | 12 | 6 | 0 | 0 | 8 | 2 | - | |
Lee et al[17], 2019 | 21 | 0.4 | 4.1 | 7.8 | 15 | 1 | 4 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 2 | - | - | |
Abutaka et al[74], 2020 | 17 | 1.5 (1-6) | 2.62 (1.2-7) | 7.5 (3-18) | 6 | 3 | 11 | 0 | 6 | 0 | 1 | 4 | 0 | 0 | HP (1); IP(1) | 100 | 1 | 64.7 |
Kang et al[45], 2020 | 30 | 4.3 | 1.6 (0.3-7.1) | 7 | 5 | 18 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Rectal stenosis (1), Rectal sinus (1), Anastomosis site dehiscence (1) | 1 | - | - |
Goldenshluger et al[50], 2020 | 23 | 2.65 | 4.07 | 7.4 | 10 | 1 | 6 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | Granulation (6) | - | - | 82.6 |
Ref. | Pts, n (%) | No. of recurrence | Pathology | RM status | Risk factor | Time to recurrence (months) | Type | Treatment |
Hompes et al[56], 2012 | 14 | 1 | TVA | + | Absence | 6 | L | Refuse treatment |
Ragupathi et al[59], 2012 | 20 | 1 | VA | - | Absence | 7 | L | Re-TAMIS |
Albert et al[30], 2013 | 50 | 1 | VA | + | Absence | 18 | L | Re-TAMIS |
1 | T1 sm3 adenocarcinoma | - | LVI, DI | 6 | L | Re-TAMIS | ||
Schiphorst et al[53], 2014 | 37 | 1 | Tis | - | Absence | 9 | L | Re-TAMIS |
1 | Adenoma | + | Absence | 8 | L | Re-TAMIS | ||
Gill et al[62], 2015 | 32 | 2 | FAP; sigmoid colon cancer | ND | Absence | NA | Non-local recurrent disease | NA |
Quaresima et al[63], 2016 | 31 | 1 | Adenoma | + | Absence | 18 | L | Colonoscopic resection |
Keller et al[35], 2016 | 75 | 1 | T1 adenocarcinoma | - | DI | 9 | L | APR |
3 | Adenoma | - | NA | NA | L | Re-TAMIS | ||
1 | Adenoma | - | NA | NA | L | Closed surveillance | ||
Sumrien et al[43], 2016 | 28 | 1 | Adenoma | - | NA | NA | L | Endoscopic snaring |
1 | Rectal cancer | NA | NA | NA | L | NA | ||
1 | Rectal cancer | NA | NA | 11 | L | Palliative radiotherapy | ||
1 | Unresectable rectal cancer | + | Palliative debulking | NA | L | Required further endoscopic resection | ||
Melin et al[64], 2016 | 29 | 1 | Adenoma | + | Absence | NA | L | Re-TAMIS |
1 | T1 adenocarcinoma | - | DI | 10 | L | APR, neoadjuvant CRT | ||
Mege et al[65], 2017 | 33 | 1 | Rectal cancer | NA | NA | NA | NA | NA |
Lee et al[24], 2018 | 200 | 1 | TVA | + | Absence | 17.6 | L | Re-TAMIS (index operation) |
2 | Adenoma | + | Absence | NA | L | Re-TAMIS | ||
1 | Tis carcinoma in situ | - | Absence | 15 | Re-TAMIS | |||
1 | Tis carcinoma in situ | - | Absence | 11 | Re-TAMIS | |||
1 | T1 adenocarcinoma | - | Absence | 17.5 | L, D (lung) | Re-TAMIS, chemoradiation | ||
1 | T1 adenocarcinoma | - | PD | 6.8 | D (lung) | Chemotherapy | ||
1 | T2 adenocarcinoma | - | DI | 10.8 | Definitive chemoradiation | |||
1 | T2 adenocarcinoma | - | DI | 28.9 | Robotic LAR | |||
1 | T3 adenocarcinoma | - | DI | 2.1 | D (lung) | Refuse treatment | ||
1 | T2 adenocarcinoma | - | DI | 12 | L, D | Refuse treatment | ||
García-Flórez et al[66], 2017 | 32 | 1 | T3 adenocarcinoma | - | DI | 12 | L | Radical surgery |
1 | T2 adenocarcinoma | - | DI | 8 | L | Radical surgery | ||
1 | Adenoma | - | NA | NA | L | NA | ||
Caycedo-Marulanda et al[44], 2017 | 50 | 1 | Adenoma | NA | NA | 13 | L | Re-TAMIS |
1 | NA | NA | NA | 35 | L (presacral mass), D (multiple liver) | Palliative chemotherapy | ||
1 | T2 adenocarcinoma | + | DI | 16 | L | Re-TAMIS, palliative chemotherapy | ||
1 | T2 adenocarcinoma | NA | DI | NA | L | APR | ||
Clermonts et al[67], 2017 | 42 | 1 | T1 adenocarcinoma | - | NA | 9 | L | Re-TAMIS |
Lee et al[68], 2017 | 35 | 1 | T1 adenocarcinoma | NA | NA | 3 | L (TAMIS site) | Hartmann`s operation |
1 | T2 adenocarcinoma | NA | DI | 40 | L (perirectal LN) | Mass excision, chemotherapy | ||
1 | T2 adenocarcinoma | NA | DI | 16 | L (perirectal LN), D (liver) | Chemotherapy | ||
1 | T2 adenocarcinoma | NA | DI | 37 | D (lung) | Chemotherapy | ||
1 | T0 adenocarcinoma | NA | NA | 4 | D (lung) | Wedge resection, chemotherapy | ||
Westrich et al[72], 2019 | 38 | 4 | Adenoma | 26 | L | re-TAMIS | ||
1 | T1 adenocarcinoma | Closed RM (1 mm) | NA | 9 | L | APR | ||
1 | T1 adenocarcinoma | - | PNI | 24 | L, D | Adjuvant radiotherapy, chemotherapy | ||
1 | T3 adenocarcinoma | - | DI | 10 | L | Adjuvant radiotherapy | ||
2 | NA | NA | NA | NA | D |
Ref. | Pts, n (%) | Complications, n (%) | Type of complications, n (%) | Reoperation | Re-admission | Conversion | Treatment of PPC |
Van den Boezem et al[55], 2011 | 12 | 1 | Bleeding (1) | 0 | 0 | TAE (2) | 0 |
Hompes et al[32], 2014 | 14 | 2 | Fever (1); Bleeding (1) | Positive for deep margin (1) | 0 | CAD fail (1); TEM assist (1) | 0 |
Barendse et al[57], 2012 | 15 | 2 | Pneumoscrotum (1); Hemorrhage (1) | 0 | Bleeding (1) | TEM (2) | 0 |
Ragupathi et al[59], 2012 | 20 | 1 | Abscess (1) | Inadequate surgical margin within 1mm (2) | 0 | 0 | 0 |
Albert et al[30], 2013 | 50 | 4 | Bleeding (1); Scrotal emphysema (1); PPC (1); COPD exacerbation (1) | 0 | Bleeding (1) | 0 | TAMIS repair (1) |
Sevá-Pereira et al[61], 2014 | 5 | 1 | Partial dehiscence of the suture line (1) | 0 | L-LAR (1) | ||
McLemore et al[27], 2014 | 32 | 8 | FI (3); UTI (1); CD diarrhea (1); Afib (1); Rectal stenosis (1); Bleeding (1) | 0 | Bleeding (1) | TAE (1) | 0 |
Schiphorst et al[53], 2014 | 37 | 6 | Rectal perforation (2); Heamorrhage (2); Abscess (1); Rectal stricture (1) | Pelvic abscess (1) | Bleeding (3); Pelvic abscess (1) | L-AR (1) | L-AR (1). Pelvic abscess drainage (1) |
Lee and Lee[28], 2014 | 25 | 1 | POUR (1) | 0 | 0 | 0 | 0 |
Hahnloser et al[33], 2015 | 75 | 21 | Local infection (6); Postoperative bleeding (5); Intraoperative bleeding (3); Penetrate peritoneal cavity (3); Pneumoscrotum (3); UTI (2); POUR (2) | Rectal perforation (1) | NA | TAMIS + LR (2), Open laparotomy (1) | TAMIS + LR (2), Open laparotomy (1) |
Gill et al[62], 2015 | 32 | 16 | Bleeding (4); Diarrhea (4); POUR (3); Perianal pain (2); Ulceration (4); Hypovolemia (1); Rectal abscess (1); Aspiration pneumonia (1); FI (1) | Rectal perforation (1) | Aspiration penumoia (1); Rectal abcess (1) | TEM (1) | 0 |
Quaresima et al[63], 2016 | 31 | 8 | Penetrate peritoneal cavity (5); UTI (1); Subcutaneous emphysema (1); Hemorrhoidal thrombosis (1) | 0 | 0 | TAE (4) | TAMIS repair (4); TAE (1) |
Keller et al[35], 2016 | 75 | 3 | Bleeding (1); Rectal stricture (1); Rectovaginal fistula (1) | 0 | Rectal bleeding (1) | TAMIS + LR (2), DS (1), Diagnostic laparoscopy (1) | TAMIS + LR (1); TAMIS + DS (1) |
Sumrien et al[43], 2016 | 28 | 10 | POUR (6); Bleeding (1); PPC (1); Stricture (1); Fever (1) | Bleeding (1) | Rectal bleeding (1) | L-AR (2), O-AR (1), Endoscopic debulking (1) | TAMIS repair (1) |
Verseveld et al[52], 2016 | 24 | 2 | Bleeding (2) | Re-bleeding (1) | 1 | 0 | NA |
Melin et al[64], 2016 | 29 | 3 | Bleeding (1); POUR (1); PPC (1) | Bleeding (1), Resudual rectal polyp (1) | 0 | 0 | TAMIS repair (1) |
Mege et al[65], 2017 | 33 | 4 | NA | NA | NA | NA | 2 |
Lee et al[24], 2018 | 200 | 31 | Intraoperative complications (8); Bleeding (9); POUR (4); Scrotal or subcutaneous emphysema (3) Mild fecal incontinence (2); Self-limiting fever (2); Perianal pain (2); Perirectal inflammation (1); DVT (1); Heparin-induced thrombocytopenia (1); Rectovaginal fistula (1); UTI (1); Non-healing rectal wound (1) | DS for nonhealing wound (1) | Nonhealing rectal wound (1); Perirectal inflammation (1), Rectovaginal fistula (1) | TAMIS + LR (4) | TAMIS repair (4); TAMIS + LR (4) |
García-Flórez et al[66], 2017 | 32 | 13 | Fever (3); Hematuria (3); Rectal bleeding (3); PPC (2); Purulent peritonitis (1); Stenosis (1) | 1 | 1 | 0 | Transanal repair (2) |
Caycedo-Marulanda et al[44], 2017 | 50 | 13 | Bleeding (4); UTI (1); Suture line leak (1); POUR (1); PPC (5); Anal structure (1) | Penetrate peritoneal cavity (1) | Bleeding (4) | Hybrid (3) | Transanal repair (5) |
Clermonts et al[67], 2017 | 42 | 6 | Hemorrhage (4); Abscess (1); Rectal stricture (1) | Pelvic abscess (1) | 4 | 0 | 0 |
Lee et al[42], 2017 | 181 | 16 | Bleeding (4); Local infection (6); POUR (2); Complication requiring operation (2) | 2 | NA | LR (2); DS (1) | TAMIS repair (4), LR (2) |
Lee et al[68], 2017 | 35 | 1 | Suture line dehiscence (1) | 0 | 0 | 0 | 0 |
Clermonts et al[67], 2017 | 37 | 4 | Bleeding (3); Abscess (1) | Pelvic abscess (1) | 4 | 0 | 0 |
Llano et al[71], 2019 | 27 | 6 | PPC (2); Rectal bleeding (1); POUR (1); Advanced cancer (1); Stenosis (1) | 0 | 0 | LR (1) | TAMIS repair (1); LR (1) |
Westrich et al[72], 2019 | 38 | 8 | Fever (4); Bleeding (2); PPC (1); Major complication (1) | Rectal perforation (1) | Rectal perforation (2), bleeding (2) | 0 | TAMIS repair (1) |
Van den Eynde et al[73], 2019 | 68 | 19 | Bleeding (1); Complications ≥ grade 3 (1) | Bleeding (5) | 3 | NA | NA |
Lee et al[17], 2019 | 21 | 2 | POUR (1); PPC (1) | 0 | 0 | LR (1) | LR (1) |
Abutaka et al[74], 2020 | 17 | 3 | Bleeding (1); PPC (2) | 0 | 0 | LR (1) | TAMIS repair (1); LR (1) |
Kang et al[45], 2020 | 30 | 4 | Diarrhea (2); FI (1); Fluid collection (1) | 0 | 0 | TAE (2) | 0 |
Goldenshluger et al[50], 2020 | 23 | 3 | Bleeding (1); Fever (1) | 0 | 0 | 0 | 0 |
- Citation: Kim MJ, Lee TG. Transanal minimally invasive surgery using laparoscopic instruments of the rectum: A review. World J Gastrointest Surg 2021; 13(10): 1149-1165
- URL: https://www.wjgnet.com/1948-9366/full/v13/i10/1149.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v13.i10.1149